Fred Ramsdell

Fred is chief scientific officer at the Parker Institute for Cancer Immunotherapy, where he leads the development of collaborative research programs. Prior to joining the Parker Institute, Fred served as vice president at aTyr Pharma, helped establish Novo Nordisk’s Inflammation Research Center in Seattle and led immunobiology discovery efforts at ZymoGenetics and Darwin Molecular/Celltech Pharma.

Fred earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles. After a fellowship at the National Institutes of Health, Fred joined Immunex, studying T cell activation and tolerance, including the identification and characterization of various tumor necrosis factors and their receptors. The Royal Swedish Academy of Sciences honored Fred and two other scientists with the Crafoord Prize for their pioneering work related to regulatory T cells and the role of the FOXP3 gene.